CAMBRIDGE, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that Stephen M. Gansler will join the Company as senior vice president of Human Resources and a member of the executive team. Mr. Gansler brings to Millennium more than 25 years of senior management experience in human resources and labor relations, including 20 years at the Johnson & Johnson Family Of Companies. Mr. Gansler is succeeding Linda Pine, who is retiring from her position as senior vice president of Human Resources after 12 years with the Company. Ms. Pine will serve as a part-time advisor until her planned retirement in 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
“Mr. Gansler’s expertise in many aspects of human resources including employee development, retention and recruitment, together with his demonstrated ability to provide strategic direction and leadership, will be important as we continue to grow one of the greatest assets of Millennium, our people,” said Deborah Dunsire, M.D., president and chief executive officer. “I would also like to thank Linda for her passion in helping to build a company over the past 12 years which has a strong commitment to its people and a culture of respect and openness.”
Mr. Gansler most recently was vice president of Human Resources at Synta Pharmaceuticals, a biotechnology company focused on oncology and inflammation. Prior to joining Synta, he served as senior vice president of Human Resources for the Covanta Energy Corporation. He has also held a number of senior human resources positions and was a member of the management board for several companies within the Johnson & Johnson Family Of Companies, including DePuy, Inc., J&J Healthcare Systems, J&J Vision Products and J&J Orthopedics. During his 20 years with J&J, Mr. Gansler developed and implemented human resource strategies that supported businesses with annual revenue from $100 million to more than $1 billion, helped to shape worldwide leadership development and succession planning, and established recognition and incentive programs to enhance a high involvement, team-oriented corporate culture. He began his career in labor relations at General Motors Corporation.
“Millennium has a reputation for cultivating innovation while demonstrating a strong commitment to employees,” said Mr. Gansler. “I am very excited about the opportunity to build on this foundation and believe that my experiences are well-suited to meet the dynamic needs of the organization.”
Mr. Gansler graduated with a B.I.A. from General Motors Institute, now known as Kettering University, and received an M.B.A. and J.D. from Seton Hall University.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company’s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative candidate products. The Company’s website is http://www.millennium.com.
This press release contains “forward-looking statements,” including statements about the Company’s growth, discovery and development of product and shareholder value. Various important risks may cause the Company’s actual results to differ materially from the results indicated by these forward- looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company’s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company’s products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Editor’s Note: This release is available on the Media section of the Millennium website at http://www.millennium.com
Contact:
Theresa McNeely (media) Kyle Kuvalanka (investors) (617) 679-7405 (617) 761-4734
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comMillennium Pharmaceuticals, Inc.
CONTACT: Theresa McNeely, +1-617-679-7405, or Kyle Kuvalanka,+1-617-761-4734, both of Millennium Pharmaceuticals, Inc.
Web site: http://www.millennium.com/
Company News On-Call: http://www.prnewswire.com/comp/114562.html /
